Pluristem’s goal is to provide patients, physicians and healthcare systems around the globe with standardized, easy to use and highly effective PLX cell products that need no genetic or tissue matching prior to administration. We are active with many respectful regulatory agencies worldwide to advance our clinical programs towards marketing. Part of our clinical development strategy is to achieve product approval through advanced regulatory pathways allowing for early marketing approval.
Our leading programs in Muscle regeneration following hip fracture surgery and Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 are in advanced stages of development. Earlier stage clinical programs include a Phase I study in incomplete recovery following bone marrow transplantation, and a Phase II study in chronic Graft Versus Host Disease (cGvHD).